Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Equity Ratio (2016 - 2025)

Historic Equity Ratio for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to 0.62.

  • UroGen Pharma's Equity Ratio fell 83804.97% to 0.62 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.62, marking a year-over-year decrease of 83804.97%. This contributed to the annual value of 0.03 for FY2024, which is 9157.53% up from last year.
  • Latest data reveals that UroGen Pharma reported Equity Ratio of 0.62 as of Q3 2025, which was down 83804.97% from 0.45 recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Equity Ratio peaked at 0.79 during Q1 2021, and registered a low of 1.45 during Q2 2023.
  • In the last 5 years, UroGen Pharma's Equity Ratio had a median value of 0.2 in 2024 and averaged 0.23.
  • As far as peak fluctuations go, UroGen Pharma's Equity Ratio crashed by 103785.91% in 2022, and later surged by 13896.49% in 2024.
  • Over the past 5 years, UroGen Pharma's Equity Ratio (Quarter) stood at 0.07 in 2021, then crashed by 1037.86% to 0.66 in 2022, then soared by 44.5% to 0.37 in 2023, then surged by 91.58% to 0.03 in 2024, then plummeted by 1924.2% to 0.62 in 2025.
  • Its Equity Ratio stands at 0.62 for Q3 2025, versus 0.45 for Q2 2025 and 0.19 for Q1 2025.